Photo of A. James Moser,  MD, FACS

A. James Moser, MD, FACS

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2633
Fax: (617) 667-7756


ajmoser@bidmc.harvard.edu

A. James Moser, MD, FACS

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Executive Director, Institute for Hepatobiliary and Pancreatic Surgery, Surgical Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am dedicated to the care of patients with lethal diseases, particularly pancreatic cancer and pancreatitis. My career in clinical innovation and expertise combines my undergraduate education in physical chemistry and mathematics with prognostic modeling of patient outcomes relevant to cancer and complex pancreatic surgery. My objective is to personalize treatment for pancreatic cancer: a horrific disease for which 70% of Americans currently elect to do nothing, both out of the perceived futility of current therapy as well as their justifiable fear of surgery. This career focus has given my translational research and clinical activities a singular purpose, and all of my teaching and philanthropic efforts are dedicated to it. I focus on building a team dedicated to the multidisciplinary treatment of pancreatic cancer. As Co-Director of the UPMC Pancreatic Cancer Center, I led efforts which increased annual patient volume four-fold, established the first multidisciplinary clinic within UPMC Cancer Centers, and pioneered the application of robotic technology to complex pancreatic diseases to reduce the pain of surgery and stress of treatment. The foundation of these efforts has been our translational research focus on validating predictive models both to specify the risk of surgery as well as to predict a patient’s likely survival afterward. Transparency and teamwork are the key ingredients in these efforts. My research effort has been funded generously by the philanthropy of patients and families affected by this disease, and I owe our success to their enduring partnership.

 

Publications

Powered by Harvard Catalyst
  • Boone BA, Zenati M, Hogg ME, Steve J, Moser AJ, Bartlett DL, Zeh HJ, Zureikat AH. Assessment of Quality Outcomes for Robotic Pancreaticoduodenectomy: Identification of the Learning Curve. JAMA Surg 2015. PubMed
  • Kim CH, Ling DC, Wegner RE, Flickinger JC, Heron DE, Zeh H, Moser AJ, Burton SA. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol 2014; 8:240. PubMed
  • Demeure MJ, Sielaff T, Koep L, Prinz R, Moser AJ, Zeh H, Hostetter G, Black J, Decker A, Rosewell S, Bussey KJ, Von Hoff D. Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimen repository. Pancreas 2010; 39:949-54. PubMed
  • Sanders MK, Moser AJ, Khalid A, Fasanella KE, Zeh HJ, Burton S, McGrath K. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc 2010; 71:1178-84. PubMed
  • Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2011; 6:955-964. PubMed
  • Franko J, Greer JB, Moran CM, Khalid A, Moser AJ. Multimodality therapy for pancreatic cancer. Gastroenterol Clin North Am 2007; 36:391-411, x. PubMed
  • Whitcomb DC, Khalid A, Slivka A, McGrath K, Moser AJ, Bell RH. Conference report for APA postgraduate course: clinical controversies in pancreatobiliary diseases. Pancreas 2005; 31:218-20. PubMed
  • Khalid A, McGrath KM, Zahid M, Wilson M, Brody D, Swalsky P, Moser AJ, Lee KK, Slivka A, Whitcomb DC, Finkelstein S. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3:967-73. PubMed
  • Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005; 54:254-64. PubMed
  • Cheung O, Kandil H, Moser AJ, Swalsky PA, Sasatomi E, Finkelstein SD. Primary duodenal carcinoma showing divergent growth patterns as determined by microdissection-based mutational genotyping. Arch Pathol Lab Med 2003; 127:861-4. PubMed
  • Moser AJ. Benign Biliary Strictures. Curr Treat Options Gastroenterol 2001; 4:377-387. PubMed
  • Baumgartner JM, Krasinskas A, Dauoadi M, Zureikat A, Marsh JW, Lee KKL, Bartlett DL, Moser AJ*, Zeh HJ III. Distal pancreatectomy with en bloc celiac axis resection for Locally Advanced Pancreatic Adenocarcinoma Following Neoadjuvant Therapy. J Gastrointest Surg 2012.
  • Daouadi M, Zureikat AH, Zenati MS, Choundry MA, Tsung A, Bartlett DL, Hughes SH, Lee KK, Moser AJ* (equal contribution), Zeh HJ III. Robot-Assisted Minimally-Invasive Distal Pancreatecomy is Superior to the Laparoscopic Technique. Annals of Surgery Ann Surg 2012.
  • Bottino R, Bertera S, Grupillo M, Melvin PR, Humar A, Mazariegos G, Moser AJ, Walsh RM, Fung J, Gelrud A, Slivka A, Soltys K, Wijkstrom M, Trucco M. Isolation of human islets for autologous islet transplantation in children and adolescents with chronic pancreatitis. Transplantation 2012.
  • Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ*, Zeh HJ 3rd. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 2011.
  • Moser AJ, Abedin MZ, Roslyn JJ. The pathogenesis of gallstone formation. Adv Surg 1993; 26:357-86. PubMed
Hide